HTG Molecular Diagnostics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

February 7, 2018 at 8:00 AM EST

TUCSON, Ariz., Feb. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that management will present in a fireside chat at the LEERINK Partners 7th Annual Global Healthcare Conference, being held February 14-15 in New York City.

Presentation Details:
Date: Thursday, February 15
Time: 2:00pm Eastern Time
Location: The Lotte New York Palace Hotel, Henry Room

About HTG:
Headquartered in Tucson, Arizona, the mission of HTG is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates highly multiplexed molecular profiling of small samples for next-generation sequencing, received its first US patent in 2014. Continuous improvements led to the 2017 launch of HTG’s new direct-target sequencing chemistry for DNA analysis offered in the company’s VERI/O services laboratory.

CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com

TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
tjjohnson@htgmolecular.com

Primary Logo

Source: HTG Molecular Diagnostics, Inc.